{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-06T10:37:24.602723+00:00","company":{"ticker":"EYPT","cik":1314102,"company_name":"EyePoint, Inc."},"pagination":{"limit":100,"returned":8,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"a3ae0033ce439c22c098cafa754585cc7c8148ab","cik":1314102,"ticker":"EYPT","company_name":"EyePoint, Inc.","filed_at":"2026-05-06T23:59:59+00:00","payload":{"eps_text":"($0.99) per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss was $84.8 million","period_text":"first quarter ended March 31, 2026","report_date":"2026-05-06","result_type":"reported_results","revenue_text":"$0.7 million"},"claim":"EyePoint, Inc. reported first quarter ended March 31, 2026 results: revenue $0.7 million, net income net loss was $84.8 million, EPS ($0.99) per share.","evidence_excerpt":"or DURAVYU-related ocular or systemic SAEs. Review of Results for the First Quarter Ended March 31, 2026 For the first quarter ended March 31, 2026, total net revenue was $0.7 million compared to $24.5 million for the corresponding period in 2025. The decrease was primarily driven by the recognition of remaining deferred revenue related to the Company’s 2023","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-207537","anchor_url":"https://secwatch.observer/filing/0001193125-26-207537#claim-a3ae0033ce439c22c098cafa754585cc7c8148ab","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1314102/000119312526207537/0001193125-26-207537-index.htm"},{"fact_type":"governance_change","fact_key":"eea690b3ae4fdaaec5d0b7d4239af98b59903e39","cik":1314102,"ticker":"EYPT","company_name":"EyePoint, Inc.","filed_at":"2025-12-08T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-12-08","item_codes_triggered":["5.03"],"summary_text":"On December 8, 2025, the Company filed a certificate of amendment to its Certificate of Incorporation to change its name from 'EyePoint Pharmaceuticals, Inc.' to 'EyePoint, Inc.', effective December 8, 2025."},"claim":"EyePoint, Inc.: On December 8, 2025, the Company filed a certificate of amendment to its Certificate of Incorporation to change its name from 'EyePoint Pharmaceuticals, Inc.' to 'EyePoint, Inc.', effective December 8, 2025 (effective 2025-12-08).","evidence_excerpt":"On December 8, 2025, EyePoint, Inc. (the “Company”) filed a certificate of amendment (the “Certificate of Amendment”) to its Certificate of Incorporation, as amended, solely to change the Company’s name from “EyePoint Pharmaceuticals, Inc.” to “EyePoint, Inc.” The name change became effective on December 8, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-25-310731","anchor_url":"https://secwatch.observer/filing/0001193125-25-310731#claim-eea690b3ae4fdaaec5d0b7d4239af98b59903e39","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1314102/000119312525310731/0001193125-25-310731-index.htm"},{"fact_type":"executive_change","fact_key":"90646969be","cik":1314102,"ticker":"EYPT","company_name":"EyePoint, Inc.","filed_at":"2025-01-08T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-01-08","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Dr. Reginald Sanders was appointed as Director at EyePoint, Inc..","evidence_excerpt":"appointed Dr. Reginald Sanders, M.D. to fill the vacancy on the Board, effective January 8, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-25-003280","anchor_url":"https://secwatch.observer/filing/0000950170-25-003280#claim-90646969be","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1314102/000095017025003280/0000950170-25-003280-index.htm"},{"fact_type":"executive_change","fact_key":"1f24234df8","cik":1314102,"ticker":"EYPT","company_name":"EyePoint, Inc.","filed_at":"2024-09-04T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-09-03","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Fred Hassan was appointed as Director at EyePoint, Inc..","evidence_excerpt":"the Board, upon the recommendation of the Governance and Nominating Committee of the Board (the \"Governance and Nominating Committee\"), reduced the size of the Board from nine to eight members and appointed Fred Hassan to fill the remaining vacancy on the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-103097","anchor_url":"https://secwatch.observer/filing/0000950170-24-103097#claim-1f24234df8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1314102/000095017024103097/0000950170-24-103097-index.htm"},{"fact_type":"executive_change","fact_key":"b5ea8f03ca","cik":1314102,"ticker":"EYPT","company_name":"EyePoint, Inc.","filed_at":"2024-09-04T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-09-03","interim":false,"role":"Director","role_category":"director","successor_name":"Fred Hassan","successor_named":true},"claim":"Anthony P. Adamis resigned as Director at EyePoint, Inc..","evidence_excerpt":"On September 3, 2024, David R. Guyer, M.D. and Anthony P. Adamis, M.D. resigned from the Board of Directors (the \"Board\") of EyePoint Pharmaceuticals, Inc. (the \"Company\") and all committees thereof, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-103097","anchor_url":"https://secwatch.observer/filing/0000950170-24-103097#claim-b5ea8f03ca","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1314102/000095017024103097/0000950170-24-103097-index.htm"},{"fact_type":"executive_change","fact_key":"807b1b6c57","cik":1314102,"ticker":"EYPT","company_name":"EyePoint, Inc.","filed_at":"2024-09-04T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-09-03","interim":false,"role":"Director","role_category":"director","successor_name":"Fred Hassan","successor_named":true},"claim":"David R. Guyer resigned as Director at EyePoint, Inc..","evidence_excerpt":"On September 3, 2024, David R. Guyer, M.D. and Anthony P. Adamis, M.D. resigned from the Board of Directors (the \"Board\") of EyePoint Pharmaceuticals, Inc. (the \"Company\") and all committees thereof, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-103097","anchor_url":"https://secwatch.observer/filing/0000950170-24-103097#claim-807b1b6c57","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1314102/000095017024103097/0000950170-24-103097-index.htm"},{"fact_type":"earnings_release","fact_key":"8b537acfe026c51ac15ea7efa6852f24f7a3609b","cik":1314102,"ticker":"EYPT","company_name":"EyePoint, Inc.","filed_at":"2024-05-08T23:59:59+00:00","payload":{"eps_text":"($0.55) per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$29.3 million","period_text":"the first quarter ended March 31, 2024","report_date":"2024-05-08","result_type":"reported_results","revenue_text":"$11.7 million"},"claim":"EyePoint, Inc. reported the first quarter ended March 31, 2024 results: revenue $11.7 million, net income $29.3 million, EPS ($0.55) per share.","evidence_excerpt":"For the first quarter ended March 31, 2024, total net revenue was $11.7 million compared to $7.7 million for the quarter ended March 31, 2023. Net product revenue for the first quarter was $0.7 million, compared to net product revenues for the first quarter ended March 31, 2023 of $7.4 million. This decrease in net product revenue resulted from the out-license of the YUTIQ franchise in May 2023, completing the strategic pivot from a commercial company to a biopharmaceutical pipeline-focused company. Net revenue from royalties and collaborations for the first quarter ended March 31, 2024 totaled $11.0 million compared to $0.3 million in the corresponding period in 2023. This increase was primarily due to partial recognition of deferred revenue from the license of the YUTIQ franchise, which begun in 2Q 2023 and will be recognized over a 2-year period in connection with the delivery of YUTIQ supply units. Operating expenses for the first quarter ended March 31, 2024 totaled $45.0 million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-055055","anchor_url":"https://secwatch.observer/filing/0000950170-24-055055#claim-8b537acfe026c51ac15ea7efa6852f24f7a3609b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1314102/000095017024055055/0000950170-24-055055-index.htm"},{"fact_type":"earnings_release","fact_key":"06edc37a321e871e4b97a072dcced8ab00fe409d","cik":1314102,"ticker":"EYPT","company_name":"EyePoint, Inc.","filed_at":"2024-03-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth quarter and year ended December 31, 2023","report_date":"2024-03-07","result_type":"reported_results","revenue_text":null},"claim":"EyePoint, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.","evidence_excerpt":"On March 7, 2024, EyePoint Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023 and certain other information.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-027582","anchor_url":"https://secwatch.observer/filing/0000950170-24-027582#claim-06edc37a321e871e4b97a072dcced8ab00fe409d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1314102/000095017024027582/0000950170-24-027582-index.htm"}]}